BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García-Díaz N, Piris MÁ, Ortiz-Romero PL, Vaqué JP. Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers (Basel) 2021;13:1931. [PMID: 33923722 DOI: 10.3390/cancers13081931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Parilla M, Quesada AE, Medeiros LJ, Thakral B. An update on genetic aberrations in T-cell neoplasms. Pathology 2023;55:287-301. [PMID: 36801152 DOI: 10.1016/j.pathol.2022.12.350] [Reference Citation Analysis]
2 Ropio J, Prochazkova-Carlotti M, Batista R, Pestana A, Chebly A, Ferrer J, Idrissi Y, Cappellen D, Durães C, Boaventura P, Vinagre J, Azzi-Martin L, Poglio S, Cabeçadas J, Campos MA, Beylot-Barry M, Sobrinho-Simões M, Merlio JP, Soares P, Chevret E. Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas. Genes (Basel) 2023;14. [PMID: 36833366 DOI: 10.3390/genes14020439] [Reference Citation Analysis]
3 Boh E, Kuraitis D, Jacobson A, Sikes M. Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma. Dermatol Ther (Heidelb) 2023;13:835-42. [PMID: 36729236 DOI: 10.1007/s13555-023-00895-2] [Reference Citation Analysis]
4 Peiffer L, Gambichler T, Buus TB, Horny K, Gravemeyer J, Furtmann F, Spassova I, Kubat L, Susok L, Stranzenbach R, Srinivas N, Ødum N, Becker JC. Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomics. Front Oncol 2023;13:1090592. [PMID: 36761972 DOI: 10.3389/fonc.2023.1090592] [Reference Citation Analysis]
5 Fay CJ, Awh KC, LeBoeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol 2022;12:1071171. [PMID: 36713518 DOI: 10.3389/fonc.2022.1071171] [Reference Citation Analysis]
6 Dutta S, Ghosh S, Mishra A, Ghosh R. Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment. J Proteins Proteom 2022. [DOI: 10.1007/s42485-022-00100-6] [Reference Citation Analysis]
7 Kwesi-maliepaard EM, Malik M, van Welsem T, van Doorn R, Vermeer MH, Vlaming H, Jacobs H, van Leeuwen F. DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1032958] [Reference Citation Analysis]
8 Patil K, Kuttikrishnan S, Khan AQ, Ahmad F, Alam M, Buddenkotte J, Ahmad A, Steinhoff M, Uddin S. Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. Semin Cancer Biol 2022;86:382-99. [PMID: 34906723 DOI: 10.1016/j.semcancer.2021.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Assaf C, Dobos G. Neue Therapieansätze und Kombinationstherapien bei kutanen T-Zell-Lymphomen. Dermatologie 2022;73:782-787. [DOI: 10.1007/s00105-022-05053-x] [Reference Citation Analysis]
10 Pileri A, Cavicchi M, Bertuzzi C, Righi S, Zengarini C, Sabattini E, Roncador G, Agostinelli C. TOX Expression in Mycosis Fungoides and Sezary Syndrome. Diagnostics 2022;12:1582. [DOI: 10.3390/diagnostics12071582] [Reference Citation Analysis]
11 Cristofoletti C, Bresin A, Fioretti M, Russo G, Narducci MG. Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome. Cancers (Basel) 2022;14:2847. [PMID: 35740513 DOI: 10.3390/cancers14122847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pietzsch L, Körholz J, Boschann F, Sergon M, Dorjbal B, Yee D, Gilly V, Kämmerer E, Paul D, Kastl C, Laass MW, Berner R, Jacobsen EM, Roesler J, Aust D, Lee-Kirsch MA, Snow AL, Schuetz C. Hyper-IgE and Carcinoma in CADINS Disease. Front Immunol 2022;13:878989. [PMID: 35651609 DOI: 10.3389/fimmu.2022.878989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Banciu ML, Dobrica EC, Soare C, Malciu AM, Voiculescu VM. Healthcare Disparities in the Management of Indolent Mycosis Fungoides. Cureus 2022. [DOI: 10.7759/cureus.24098] [Reference Citation Analysis]
14 Wind SS, Jansen MAA, Rijsbergen M, van Esdonk MJ, Ziagkos D, Cheng WC, Niemeyer-van der Kolk T, Korsten J, Gruszka A, Schmitz-Rohmer D, Bonnel D, Legouffe R, Barré F, Bekkenk MW, de Haas ERM, Quint KD, Rolli M, Streefkerk HJ, Burggraaf J, Vermeer MH, Rissmann R. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers (Basel) 2022;14. [PMID: 35326659 DOI: 10.3390/cancers14061510] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kołkowski K, Trzeciak M, Sokołowska-Wojdyło M. Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas. Int J Mol Sci 2021;22:13388. [PMID: 34948183 DOI: 10.3390/ijms222413388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Dobos G, Assaf C. Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications. Br J Dermatol 2021. [PMID: 34841514 DOI: 10.1111/bjd.20895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]